2023-10-01 2024-09-30 false No description of principal activity Capium Accounts Production 1.1 12871017 2023-10-01 2024-09-30 12871017 bus:FullAccounts 2023-10-01 2024-09-30 12871017 bus:FRS102 2023-10-01 2024-09-30 12871017 bus:AuditExemptWithAccountantsReport 2023-10-01 2024-09-30 12871017 bus:SmallCompaniesRegimeForAccounts 2023-10-01 2024-09-30 12871017 bus:PrivateLimitedCompanyLtd 2023-10-01 2024-09-30 12871017 2023-10-01 2024-09-30 12871017 2024-09-30 12871017 bus:RegisteredOffice 2023-10-01 2024-09-30 12871017 core:WithinOneYear 2024-09-30 12871017 core:AfterOneYear 2024-09-30 12871017 1 2023-10-01 2024-09-30 12871017 bus:Director1 2023-10-01 2024-09-30 12871017 bus:Director1 2024-09-30 12871017 bus:Director1 2022-10-01 2023-09-30 12871017 bus:Director2 2023-10-01 2024-09-30 12871017 bus:Director2 2024-09-30 12871017 bus:Director2 2022-10-01 2023-09-30 12871017 2022-10-01 12871017 bus:LeadAgentIfApplicable 2023-10-01 2024-09-30 12871017 2022-10-01 2023-09-30 12871017 2023-09-30 12871017 core:WithinOneYear 2023-09-30 12871017 core:AfterOneYear 2023-09-30 12871017 bus:EntityAccountantsOrAuditors 2022-10-01 2023-09-30 12871017 core:ComputerEquipment 2023-10-01 2024-09-30 12871017 core:ComputerEquipment 2024-09-30 12871017 core:ComputerEquipment 2023-09-30 12871017 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2024-09-30 12871017 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2023-09-30 12871017 core:CostValuation core:Non-currentFinancialInstruments 2024-09-30 12871017 core:CostValuation core:Non-currentFinancialInstruments 2023-09-30 12871017 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-09-30 12871017 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2024-09-30 12871017 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2024-09-30 12871017 core:Non-currentFinancialInstruments 2024-09-30 12871017 core:Non-currentFinancialInstruments 2023-09-30 12871017 core:ShareCapital 2024-09-30 12871017 core:ShareCapital 2023-09-30 12871017 core:RetainedEarningsAccumulatedLosses 2024-09-30 12871017 core:RetainedEarningsAccumulatedLosses 2023-09-30 12871017 dpl:Item1 2023-10-01 12871017 dpl:Item1 2024-09-30 12871017 dpl:Item1 2022-10-01 12871017 dpl:Item1 2023-09-30 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 12871017
England and Wales

 

 

 

VIOLICOM MEDICAL LIMITED


Unaudited Financial Statements
 


Period of accounts

Start date: 01 October 2023

End date: 30 September 2024
Directors Dr B S Rodgers-Gray
Mrs J Rodgers-Gray
Registered Number 12871017
Registered Office 1 Andromeda House
Calleva Park
Aldermaston
Berkshire
RG7 8AP
Accountants Dove Marsh & Jones
1 Andromeda House
Calleva Park
Aldermaston
Berkshire
RG7 8AP
1
Director's report and financial statements
The directors present their annual report and the financial statements for the year ended 30 September 2024
Directors
The directors who served the company throughout the year were as follows:
Dr B S Rodgers-Gray
Mrs J Rodgers-Gray
Statement of directors' responsibilities
The directors are responsible for preparing the directors’ report and the financial statements in accordance with applicable law and regulation.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to
  • select suitable accounting policies and then apply them consistently
  • make judgments and accounting estimates that are reasonable and prudent
  • prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business


The directors are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. The directors are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

This report was approved by the board and signed on its behalf by:


----------------------------------
Dr B S Rodgers-Gray
Director

Date approved: 08 May 2025
2
Report to the directors on the preparation of the unaudited statutory accounts of Violicom Medical Limited for the year ended 30 September 2024.
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Violicom Medical Limited for the year ended 30 September 2024 which comprise of the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the company’s accounting records and from information and explanations you have given us.
As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at
http://rulebook.accaglobal.com/.
This report is made solely to the Board of Directors of Violicom Medical Limited, as a body, in accordance with the terms of our engagement letter dated 27 June 2024. Our work has been undertaken solely to prepare for your approval the accounts of Violicom Medical Limited and state those matters that we have agreed to state to the Board of Directors of Violicom Medical Limited, as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/factsheet163. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Violicom Medical Limited and its Board of Directors as a body for our work or for this report.
It is your duty to ensure that Violicom Medical Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of Violicom Medical Limited. You consider that Violicom Medical Limited is exempt from the statutory audit requirement for the year.
We have not been instructed to carry out an audit or a review of the accounts of Violicom Medical Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts
30 September 2024.



....................................................
Dove Marsh & Jones
Dove Marsh & Jones

1 Andromeda House
Calleva Park
Aldermaston
Berkshire
RG7 8AP
08 May 2025
3
 
 
Notes
 
2024
£
  2023
£
Fixed assets      
Tangible fixed assets 3 4,257    5,707 
4,257    5,707 
Current assets      
Debtors 4 465,999    476,975 
Cash at bank and in hand 893,997    326,448 
1,359,996    803,423 
Creditors: amount falling due within one year 5 (316,369)   (174,150)
Net current assets 1,043,627    629,273 
 
Total assets less current liabilities 1,047,884    634,980 
Net assets 1,047,884    634,980 
 

Capital and reserves
     
Called up share capital 100    100 
Profit and loss account 1,047,784    634,880 
Shareholders' funds 1,047,884    634,980 
 


For the year ended 30 September 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.
The financial statements were approved by the board of directors on 08 May 2025 and were signed on its behalf by:


-------------------------------
Dr B S Rodgers-Gray
Director
4
General Information
Violicom Medical Limited is a private company, limited by shares, registered in England and Wales, registration number 12871017, registration address 1 Andromeda House, Calleva Park, Aldermaston, Berkshire, RG7 8AP. The trading address of the company is 27 Highclere Way, Chandlers Ford, Eastleigh, Hampshire, SO5 3PQ.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by Section 1A of the standard)
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
Foreign currencies
Monetary assets and liabilities denominated in foreign currencies are translated into sterling at the rate of exchange ruling at the statement of financial position date. Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. All foreign exchange differences are included to the income statement.
Tangible fixed assets
Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Computer Equipment 25% Straight Line
2.

Average number of employees

Average number of employees during the year was 6 (2023 : 6).
3.

Tangible fixed assets

Cost or valuation Computer Equipment   Total
  £   £
At 01 October 2023 10,499    10,499 
Additions 1,410    1,410 
Disposals  
At 30 September 2024 11,909    11,909 
Depreciation
At 01 October 2023 4,792    4,792 
Charge for year 2,860    2,860 
On disposals  
At 30 September 2024 7,652    7,652 
Net book values
Closing balance as at 30 September 2024 4,257    4,257 
Opening balance as at 01 October 2023 5,707    5,707 


4.

Debtors: amounts falling due within one year

2024
£
  2023
£
Trade Debtors 464,955    475,969 
Prepayments & Accrued Income 1,044    1,006 
465,999    476,975 

5.

Creditors: amount falling due within one year

2024
£
  2023
£
Corporation Tax 214,248    120,270 
PAYE & Social Security 25,561    25,712 
Accrued Expenses 14,772    3,144 
Other Creditors 3,644    3,497 
Wages & Salaries Control Account  
Directors' Current Accounts 900    588 
VAT 57,244    20,939 
316,369    174,150 

5